Category: Medicare

Why Drug Price Negotiation Has Staying Power

In this Axios column, Drew Altman looks beyond Medicare to what’s at stake for employers and workers in the debate about the government negotiating drug prices.

KHN’s ‘What the Health?’: How to Expand Health Coverage

Democrats in Congress and the states are devising strategies to expand health coverage — through the Affordable Care Act, Medicare, Medicaid and a “public option.” But progress remains halting, at best. Meanwhile, lawmakers in Washington may have to agree on how to control prescription drug prices if they wish to finance their coverage initiatives. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Shefali Luthra of The 19th join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Michelle Andrews, who reported and wrote last month’s KHN-NPR “Bill of the Month” episode about a very expensive sleep study.

Biden Quietly Transforms Medicaid Safety Net

In a sharp shift from Trump-era policies, President Joe Biden looks at expanding Medicaid eligibility to new mothers, inmates and undocumented immigrants and adding services such as food and housing.

KHN’s ‘What the Health?’: The ACA Lives

In a surprisingly strong 7-2 decision, the Supreme Court turned back the latest constitutional challenge to the Affordable Care Act, likely heralding the end of GOP efforts to strike the law in its entirety through court action. Meanwhile, Democratic lawmakers are looking for ways to expand health benefits. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Andy Slavitt, who recently stepped down from the Biden administration’s covid response team, about his new book on the pandemic.

Public Opinion on Prescription Drugs and Their Prices

This charticle draws on recent KFF poll findings to provide an in-depth look at the public’s attitudes toward prescription drugs and their prices. Results include Americans’ opinions on drug affordability, pharmaceutical companies, and various potentia…

FDA’s Approval of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications for Medicare and Beneficiaries

The question of what would happen when a new, expensive prescription drug comes to market for a disease like Alzheimer’s that afflicts millions of people has loomed large in discussions over drug prices in the U.S. This brief analyzes the cost implicat…

Expanding Insurance Coverage Is Top Priority for New Medicare-Medicaid Chief

Chiquita Brooks-LaSure, the new head of the Centers for Medicare & Medicaid Services, said the administration will focus on getting more people insured and is interested in finding a way to alleviate the gap keeping low-income families in states that haven’t expanded Medicaid from enrolling in Affordable Care Act health plans.

KHN’s ‘What the Health?’: The Return of the Public Option

Lawmakers are working on fleshing out the concept of a “public option,” a government-run or heavily regulated insurance plan that would compete with private insurance. But the details are complicated, both substantively and politically. Meanwhile, bioethicists are debating whether the U.S. should be vaccinating low-risk adolescents against covid-19 while high-risk adults in other countries are still waiting. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Rachana Pradhan of KHN join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

Expanding Medicare to Adults at Age 60 Years—Medicare-for-More?

In this column for the JAMA Health Forum, Larry Levitt examines the implications of lowering Medicare’s age of eligibility, which is emerging as a potential pathway toward Medicare-for-all or a public option among single-payer advocates. He explores th…

Is Your Living Room the Future of Hospital Care?

In the latest sign that in-home acute care is catching on, two big players — Kaiser Permanente and the Mayo Clinic — announced plans to collectively invest $100 million into the company Medically Home to help scale up their programs.